XCUR: Bathi resik saben saham (EPS TTM) Exicure, Inc.

The rolling net income per share dynamics for Exicure, Inc. (XCUR) demonstrate the impact of express oligonucleotide delivery via air channels on financial results, where the -1.31 mark indicates the current state. Margin stability is maintained through strict cold chain control and supplier diversification. The business capitalization relies on the licensing of SNA technology, which enables deep tissue drug delivery through royalties from partners.

The scalable gene therapy model of Exicure, Inc. (XCUR) is reflected in the 12-month rolling earnings per share history. This indicator demonstrates the bottom-line financial result allocated to a single common share. The calculation excludes the impact of issuance volume, highlighting the net efficiency of capital generation. For a biotech company with low synthesis costs for drugs, growth in this value confirms the commercial success of the platform. However, purchasing the asset at a local maximum creates a risk of investment stagnation.